Key facts
- It has raised $158.2M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Suzhou Oriza Holdings Corporation.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Canhelp Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Canhelp Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Canhelp Genomics
Operator of a biotechnology platform intended to advance molecular diagnostics and personalized medicine in the field of oncology. The company offers technology that improves patient care by resolving diagnostic uncertainty with trustworthy and actionable evidence, enabling healthcare providers to achieve accurate disease diagnosis and support more personalized treatment decisions.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2015
- Employees
- 100
- Website
- canhelpgenomics.com/
- Ownership
- Privately Held (backing)
Canhelp Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Canhelp Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Canhelp Genomics in its N-PORT filings yet. We sweep new filings monthly.